Personalized medicine: Theranostics (therapeutics diagnostics) essential for rational use of tumor necrosis factor-alpha antagonists

Discovery Medicine

Volumn 15, Issue 83, 2013, Pages 201-211

  Bendtzen, Klaus ^a  

^a Rigshospitalet   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRHEUMATIC AGENT; PHARMACOLOGICAL BIOMARKER; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; COST BENEFIT ANALYSIS; DRUG ANTAGONISM; DRUG MONITORING; EUROPE; GENETIC ENGINEERING; HUMAN; IMMUNOASSAY; IMMUNOPATHOLOGY; INFLAMMATION; METHODOLOGY; PERSONALIZED MEDICINE; PHARMACEUTICS; REPORTER GENE; TREATMENT OUTCOME; UNITED STATES;

ANTIRHEUMATIC AGENTS; BIOMARKERS, PHARMACOLOGICAL; BIOPHARMACEUTICS; COST-BENEFIT ANALYSIS; DRUG MONITORING; EUROPE; GENES, REPORTER; GENETIC ENGINEERING; HUMANS; IMMUNE SYSTEM DISEASES; IMMUNOASSAY; INDIVIDUALIZED MEDICINE; INFLAMMATION; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; UNITED STATES;

EID: 84886254329     PISSN: 15396509     EISSN: 19447930     Source Type: Journal    
DOI: None     Document Type: Article

References (72)

1. Aarden L, Ruuls SR, Wolbink G. Immunogenicity of anti-tumor necrosis factor antibodies - toward improved methods of anti-antibody measurement. Curr Opin Immunol 20(4):431-435, 2008.
2. Afif W, Loftus EVJ, Faubion WA, Kane SV, Bruining DH, Hanson KA, Sandborn WJ. Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am J Gastroenterol 105(5):1133-1139, 2010.
3. Aikawa NE, JF dC, Silva CAA, Bonfa E. Immunogenicity of anti-TNF-alpha agents in autoimmune diseases. Clin Rev Allergy Immunol 38:82-89, 2010.
4. Ainsworth MA, Bendtzen K, Brynskov J. Tumor necrosis factor-alpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohn's disease. Am J Gastroenterol 103:944-948, 2008.
5. Allez M, Karmiris K, Louis E, Van Assche G, Ben-Horin S, Klein A, Van der Woude J, Baert F, Eliakim R, Katsanos K, Brynskov J, Steinwurz F, Danese S, Vermeire S, Teillaud J-L, Lémann M, Chowers Y. Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: Definitions, frequency and pharmacological aspects. J Crohn's Colitis 4(4):355-366, 2010.
6. Assasi N, Blackhouse G, Xie F, Marshall JK, Irvine EJ, Gaebel K, Robertson D, Campbell K, Hopkins R, Goeree R. Patient outcomes after anti TNF-alpha drugs for Crohn's disease. Expert Rev Pharmacoecon Outcomes Res 10(2):163-175, 2010.
7. Atzeni F, Talotta R, Benucci M, Salaffi F, Cassinotti A, Varisco V, Battellino M, Ardizzone S, Pace F, Sarzi-Puttini P. Immunogenicity and autoimmunity during anti-TNF therapy. Autoimmun Rev, epub ahead of print, Nov. 30, 2012.
8. Bartelds GM, Krieckaert CL, Nurmohamed MT, van Schouwenburg PA, Lems WF, Twisk JW, Dijkmans BA, Aarden L, Wolbink GJ. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA 305(14):1460-1468, 2011.
9. Ben-Horin S, Chowers Y. Review article: loss of response to anti-TNF treatments in Crohn's disease. Aliment Pharmacol Ther 2011.
10. Bendtzen K, Geborek P, Svenson M, Larsson L, Kapetanovic MC, Saxne T. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor Infliximab. Arthritis Rheum 54:3782-3789, 2006.
11. Bendtzen K, Ainsworth M, Steenholdt C, Thomsen OO, Brynskov J. Individual medicine in inflammatory bowel disease: monitoring bioavailability, pharmacokinetics and immunogenicity of anti-tumour necrosis factor-alpha antibodies. Scand J Gastroenterol 44(7):774-781, 2009.
12. Bendtzen K. Editorial: Is there a need for immunopharmacological guidance of anti-TNF therapies. Arthritis Rheum 63(4):867-870, 2011.
13. Bendtzen K, Svenson M. Enzyme immunoassays and radioimmunoassays for quantification of anti-TNF biopharmaceuticals and anti-drug antibodies. In: Detection and Quantification of Antibodies to Biopharmaceuticals. Practical and Applied Considerations. Tovey MG, ed. pp 83-101. John Wiley & Sons, Inc., West Sussex, UK, 2011.
14. Bendtzen K. Anti-TNF-a biotherapies: perspectives for evidence-based personalized medicine. Immunotherapy 4(11):1167-1179, 2012.
15. Brunasso AM, Puntoni M, Massone C. Drug survival rates of biologic treatments in patients with psoriasis vulgaris. Br J Dermatol 166(2):447-449, 2012.
16. Cassinotti A, Travis S. Incidence and clinical significance of immunogenicity to infliximab in Crohn's disease: A critical systematic review. Inflamm Bowel Dis 15:1264-1275, 2009.
17. Chaparro M, Guerra I, Munoz-Linares P, Gisbert JP. Systematic review: antibodies and anti-TNF-alpha levels in inflammatory bowel disease. Aliment Pharmacol Ther doi:10.1111/j.1365-2036.2012.05057.x:1-16, 2012.
18. Cheifetz A, Mayer L. Monoclonal antibodies, immunogenicity, and associated infusion reactions. Mt Sinai J Med 72(4):250-256, 2005.
19. Colombel JF, Feagan BG, Sandborn WJ, Van Assche G, Robinson AM. Therapeutic drug monitoring of biologics for inflammatory bowel disease. Inflamm Bowel Dis 18(2):349-358, 2012.
20. Danese S, Colombel JF, Reinisch W, Rutgeerts PJ. Review article: infliximab for Crohn's disease treatment - shifting therapeutic strategies after 10 years of clinical experience. Aliment Pharmacol Ther 33(8):857-869, 2011.
21. De Groot AS, Scott DW. Immunogenicity of protein therapeutics. Trends Immunol 28(11):482-490, 2007.
22. Desai D, Brightling C. TNF-alpha antagonism in severe asthma. Recent Pat Inflamm Allergy Drug Discov 4(3):193-200, 2010.
23. Descotes J, Gouraud A. Clinical immunotoxicity of therapeutic proteins. Expert Opin Drug Metab Toxicol 4(12):1537-1549, 2008.
24. Dubey S, Kerrigan N, Mills K, Scott DG. Bronchospasm associated with anti-TNF treatment. Clin Rheumatol 28(8):989-992, 2009.
25. Ebert EC, Das KM, Mehta V, Rezac C. Non-response to infliximab may be due to innate neutralizing anti-tumour necrosis factor-alpha antibodies. Clin Exp Immunol 154:325-331, 2008.
26. Emery P, Fleischmann RM, Moreland LW, Hsia EC, Strusberg I, Durez P, Nash P, Amante EJ, Churchill M, Park W, Pons-Estel BA, Doyle MK, Visvanathan S, Xu W, Rahman MU. Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: Twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis. Arthritis Rheum 60(8):2272-2283, 2009.
27. Emery P. Optimizing outcomes in patients with rheumatoid arthritis and an inadequate response to anti-TNF treatment. Rheumatology (Oxford) 51(Suppl 5):v22-v30, 2012.
28. European Medicines Agency (EMA). Guideline on immunogenicity assessment of biotechnology-derived therapeutic proteins (http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003946.pdf). pp1-18, 2007.
29. Fefferman DS, Farrell RJ. Immunogenicity of biological agents in inflammatory bowel disease. Inflamm Bowel Dis 11(5):497-503, 2005.
30. Furst DE, Keystone EC, Braun J, Breedveld FC, Burmester GR, De Benedetti F, Dorner T, Emery P, Fleischmann R, Gibofsky A, Kalden JR, Kavanaugh A, Kirkham B, Mease P, Sieper J, Singer NG, Smolen JS, Van Riel PL, Weisman MH, Winthrop K. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010. Ann Rheum Dis 70(Suppl 1):i2-i36, 2011.
31. Garces S, Demengeot J, Benito-Garcia E. The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis. Ann Rheum Dis, epub ahead of print, Dec. 6, 2012.
32. Hart MH, de Vrieze H, Wouters D, Wolbink GJ, Killestein J, de Groot ER, Aarden LA, Rispens T. Differential effect of drug interference in immunogenicity assays. J Immunol Methods 372:196-203, 2011.
33. Hwang WY, Foote J. Immunogenicity of engineered antibodies. Methods 36:3-10, 2005.
34. Jamnitski A, Bartelds GM, Nurmohamed MT, van Schouwenburg PA, van Schaardenburg D, Stapel SO, Dijkmans BA, Aarden L, Wolbink GJ. The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept. Ann Rheum Dis 70:284-288, 2010.
35. Jamnitski A, Krieckaert CL, Nurmohamed MT, Hart MH, Dijkmans BA, Aarden L, Voskuyl AE, Wolbink GJ. Patients non-responding to etanercept obtain lower etanercept concentrations compared with responding patients. Ann Rheum Dis 64(12):3850-3855, 2012.
36. Jemec GB. Predicting response to anti-TNF-alpha treatment in Hidradenitis suppurativa. Br J Dermatol 168(2):233, 2013.
37. Karmiris K, Paintaud G, Noman M, Magdelaine-Beuzelin C, Ferrante M, Degenne D, Claes K, Coopman T, Van Schuerbeek N, Van Assche G, Vermeire S, Rutgeerts P. Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease. Gastroenterology 137(5):1628-1640, 2009.
38. Korswagen LA, Bartelds GM, Krieckaert CL, Turkstra F, Nurmohamed MT, van Schaardenburg D, Wijbrandts CA, Tak PP, Lems WF, Dijkmans BA, van Vugt RM, Wolbink GJ. Venous and arterial thromboembolic events in adalimumab-treated patients with antiadalimumab antibodies: a case series and cohort study. Arthritis Rheum 63(4):877-883, 2011.
39. Krieckaert C, Rispens T, Wolbink G. Immunogenicity of biological therapeutics: from assay to patient. Curr Opin Rheumatol 24(3):306-311, 2012.
40. Krieckaert CL, Bartelds GM, Lems WF, Wolbink GJ. The effect of immunomodulators on the immunogenicity of TNF-blocking therapeutic monoclonal antibodies: a review. Arthritis Res Ther 12(5):217, 2010.
41. Kromminga A, Schellekens H. Antibodies against erythropoietin and other protein-based therapeutics: An overview. Ann N Y Acad Sci 1050:257-265, 2005.
42. Lallemand C, Kavrochorianou N, Steenholdt C, Bendtzen K, Ainsworth MA, Meritet JF, Blanchard B, Lebon P, Taylor P, Charles P, Alzabin S, Tovey MG. Reporter gene assay for the quantification of the activity and neutralizing antibody response to TNFalpha antagonists. J Immunol Methods 373(1-2):229-239, 2011.
43. Langford CA. Drug insight: anti-tumor necrosis factor therapies for the vasculitic diseases. Nat Clin Pract Rheumatol 4(7):364-370, 2008.
44. Lecluse LL, Driessen RJ, Spuls PI, de Jong EM, Stapel SO, van Doorn MB, Bos JD, Wolbink GJ. Extent and clinical consequences of antibody formation against adalimumab in patients with plaque psoriasis. Arch Dermatol 146(2):127-132, 2010.
45. Lin J, Ziring D, Desai S, Kim S, Wong M, Korin Y, Braun J, Reed E, Gjertson D, Singh RR. TNFalpha blockade in human diseases: an overview of efficacy and safety. Clin Immunol 126(1):13-30, 2008.
46. Makol A, Grover M, Guggenheim C, Hassouna H. Etanercept and venous thromboembolism: a case series. J Med Case Reports 4:12, 2010.
47. Mulleman D, Meric JC, Paintaud G, Ducourau E, Magdelaine-Beuzelin C, Valat JP, Goupille P. Infliximab concentration monitoring improves the control of disease activity in rheumatoid arthritis. Arthritis Res Ther 11(6):R178, 2009.
48. Ordas I, Mould DR, Feagan BG, Sandborn WJ. Anti-TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics-based dosing paradigms. Clin Pharmacol Ther 91(4):635-646, 2012.
49. Palekar-Shanbhag PS, Jog SV, Gaikwad SS, Chogale MM. Theranostics for cancer therapy. Curr Drug Deliv, epub ahead of print, Dec. 31, 2012.
50. Petitpain N, Gambier N, Wahl D, Chary-Valckenaere I, Loeuille D, Gillet P. Arterial and venous thromboembolic events during anti-TNF therapy: a study of 85 spontaneous reports in the period 2000-2006. Biomed Mater Eng 19(4):355-364, 2009.
51. Radstake TR, Svenson M, Eijsbouts AM, van den Hoogen FH, Enevold C, van Riel PL, Bendtzen K. Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis. Ann Rheum Dis 68(11):1739-1745, 2009.
52. Shankar G, Shores E, Wagner C, Mire-Sluis A. Scientific and regulatory considerations on the immunogenicity of biologics. Trends Biotechnol 24(6):274-280, 2006.
53. St. Clair EW, Wagner CL, Fasanmade AA, Wang B, Schaible T, Kavanaugh A, Keystone EC. The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis. Results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 46:1451-1459, 2002.
54. Steenholdt C, Svenson M, Bendtzen K, Thomsen O, Brynskov J, Ainsworth MA. Severe infusion reactions to infliximab: aetiology, immunogenicity and risk factors in patients with inflammatory bowel disease. Aliment Pharmacol Ther 34(1):51-58, 2011a.
55. Steenholdt C, Bendtzen K, Brynskov J, Thomsen OO, Ainsworth MA. Cut-off levels and diagnostic accuracy of infliximab trough levels and anti-infliximab antibodies in Crohn's disease. Scand J Gastroenterol 46(3):310-318, 2011b.
56. Steenholdt C, Al-khalaf M, Brynskov J, Bendtzen K, Thomsen O, Ainsworth MA. Clinical implications of variations in anti-infliximab antibody levels in patients with inflammatory bowel disease. Inflamm Bowel Dis 18(12):2209-2217, 2012.
57. Steenholdt C, Brynskov J, Thomsen O, Munck LK, Fallingborg J, Christensen LA, Pedersen G, Kjeldsen J, Jacobsen BA, Oxholm AS, Kjellberg J, Bendtzen K, Ainsworth MA. Treatment of secondary infliximab failure in Crohn's disease based on serum levels of infliximab and antibodies against infliximab: the Danish study of Optimizing Infliximab Therapy in Crohn's Disease (DO IT CROHN) randomized clinical trial. Digestive Disease Week, Orlando, Florida, USA, 2013.
58. Strand V, Kimberly R, Isaacs JD. Biologic therapies in rheumatology: lessons learned, future directions. Nat Rev Drug Discov 6(1):75-92, 2007.
59. Svenson M, Geborek P, Saxne T, Bendtzen K. Monitoring patients treated with anti-TNF-alpha biopharmaceuticals - assessing serum infliximab and anti-infliximab antibodies. Rheumatology 46:1828-1834, 2007.
60. Tanaka Y. Next stage of RA treatment: is TNF inhibitor-free remission a possible treatment goal? Ann Rheum Dis 72(Suppl 2):ii124-ii127, 2013.
61. Tangri S, Mothe BR, Eisenbraun J, Sidney J, Southwood S, Briggs K, Zinckgraf J, Bilsel P, Newman M, Chesnut R, Licalsi C, Sette A. Rationally engineered therapeutic proteins with reduced immunogenicity. J Immunol 174(6):3187-3196, 2005.
62. Ternant D, Aubourg A, Magdelaine-Beuzelin C, Degenne D, Watier H, Picon L, Paintaud G. Infliximab pharmacokinetics in inflammatory bowel disease patients. Ther Drug Monit 30(4):523-529, 2008.
63. van den Bemt BJ, den Broeder AA, Wolbink GJ, Hekster YA, van Riel PL, Benraad B, van den Hoogen FH. Anti-infliximab antibodies are already detectable in most patients with rheumatoid arthritis halfway through an infusioncycle: an open-label pharmacokinetic cohort study. BMC Musculoskelet Disord 12:12, 2011.
64. van der Maas A, van den Bemt BJ, Wolbink GJ, van den Hoogen FH, van Riel PL, den Broeder AA. Low infliximab serum trough levels and anti-infliximab antibodies are prevalent in rheumatoid arthritis patients treated with infliximab in daily clinical practice: results of an observational cohort study. BMC Musculoskelet Disord 13(1):184, 2012.
65. van Schouwenburg PA, Krieckaert CL, Nurmohamed M, Hart M, Rispens T, Aarden L, Wouters D, Wolbink GJ. IgG4 production against adalimumab during long term treatment of RA patients. J Clin Immunol 32(5):1000-1006, 2012.
66. Wang SL, Ohrmund L, Hauenstein S, Salbato J, Reddy R, Monk P, Lockton S, Ling N, Singh S. Development and validation of a homogeneous mobility shift assay for the measurement of infliximab and antibodies-to-infliximab levels in patient serum. J Immunol Methods 382(1-2):177-88, 2012.
67. West RL, Zelinkova Z, Wolbink GJ, Kuipers EJ, Stokkers PC, Van der Woude CJ. Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn's disease. Aliment Pharmacol Ther 28(9):1122-1126, 2008.
68. Wijbrandts CA, Dijkgraaf MG, Kraan MC, Vinkenoog M, Smeets TJ, Dinant H, Vos K, Lems WF, Wolbink GJ, Sijpkens D, Dijkmans BA, Tak PP. The clinical response to infliximab in rheumatoid arthritis is in part dependent on pretreatment tumour necrosis factor alpha expression in the synovium. Ann Rheum Dis 67(8):1139-1144, 2008.
69. Wolbink GJ, Voskuyl AE, Lems WF, de Groot E, Nurmohamed MT, Tak PP, Dijkmans BA, Aarden L. Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritis. Ann Rheum Dis 64(5):704-707, 2005.
70. Wolbink GJ, Vis M, Lems W, Voskuyl AE, de Groot E, Nurmohamed MT, Stapel S, Tak PP, Aarden L, Dijkmans B. Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum 54(3):711-715, 2006.
71. Wolbink GJ, Aarden LA, Dijkmans BA. Dealing with immunogenicity of biologicals: assessment and clinical relevance. Curr Opin Rheumatol 21(3):211-215, 2009.
72. Yanai H, Hanauer SB. Assessing response and loss of response to biological therapies in IBD. Am J Gastroenterol 106:685-698, 2011.